Abstract
events. Cholesterol in the cell membrane is produced from de novo synthesis via hydroxy-methylglutaryl coenzyme A reductase (HMG-CoA reductase) [3]. Zoledronic acid, which is an anti-osteoporotic drug assigned to a class of pharmaceuticals called bisphosphonates, effectively inhibits the enzyme farnesyl diphosphate synthase in the HMG-CoA reductase pathway which can lead to significant reduction in the osteoclast-like cell formation [4, 5]. Therefore, this effect of zoledronic acid might contribute as one of the major mechanisms for reduced bone destruction in WDLS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
